title: Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol.
abstract: Loteprednol etabonate (LE) is a glucocorticoid soft drug that is currently in development for intranasal use. The main objectives of this study were to examine the pharmacokinetics and potential effects on systemic cortisol of two intranasal suspension formulations of LE and to compare these findings with placebo and fluticasone propionate (FP, Flonase) control treatments. In this randomized, double-blind (except for FP), parallel-group study (n = 8/group), all subjects received for 14 days once daily in the morning two puffs of the following nasal spray formulations into each nostril: LE 0.1% (400 microg/day), LE 0.2% (800 microg/day), FP 0.05% (200 microg/day), and placebo. Drug trough levels were determined on days 1, 5, 12, 13, and 14, and a full pharmacokinetic profile was established on day 14, and 24-hour serum cortisol profiles were assessed prior to treatment (i.e., at baseline) and after the last dose. All subjects completed the protocol without treatment-emergent adverse findings. All formulations were rapidly absorbed (t(max) less than 1 h). The rather short mean terminal half-lives of 2.2 +/- 1.5 hours and 1.8 +/- 1.0 hours for LE 400 microg and LE 800 microg, respectively, and 4.2 +/- 1.8 hours for the 200-microg FP treatment explained the lack of any accumulation. Mean peak concentrations (C(max)) were 139 +/- 57 pg/mL with LE 400 microg and 164 +/- 54 pg/mL with LE 800 microg and thus fairly independent from dose. The 200-microg FP treatment resulted in a C(max) of only 15.5 +/- 5.9 pg/mL. Mean measured AUC(0-t) values (193 +/- 87 pg/h/mL(-1), 300 +/- 183 pg/h/mL(-1), and 40 +/- 34 pg/h/mL(-1) for LE 400 microg, LE 800 microg, and FP 200 microg, respectively) showed high variability and suggested nonlinear pharmacokinetics for the LE formulations, indicative of a less complete systemic uptake of LE from the 0.2% concentration. None of the treatments (LE 400 microg, LE 800 microg, and FP 200 microg) showed evidence for serum cortisol suppression when compared with placebo, respectively. The uptake and systemic exposure appears less complete from the 0.2% LE concentration, which principally favors this formulation for further clinical development.
authors.affiliation: Clionical Development, VIATRIS GmbH & Co., KG, Frankfurt am Main, Germany.
authors.forename: Robert
authors.initials: R
authors.lastname: Hermann
authors.forename: Mathias
authors.initials: M
authors.lastname: Locher
authors.forename: Marianne
authors.initials: M
authors.lastname: Siebert-Weigel
authors.forename: Nicole
authors.initials: N
authors.lastname: LaVallee
authors.forename: Hartmut
authors.initials: H
authors.lastname: Derendorf
authors.forename: Günther
authors.initials: G
authors.lastname: Hochhaus
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D019540:Area Under Curve; D004311:Double-Blind Method; D000068298:Fluticasone; D006207:Half-Life; D006801:Humans; D006854:Hydrocortisone / Q000502:physiology*; D000069559:Loteprednol Etabonate; D008297:Male; D016037:Single-Blind Method; D013997:Time Factors
chemical_list: D000730:Androstadienes; D000068298:Fluticasone; D006854:Hydrocortisone; D000069559:Loteprednol Etabonate